This content is from: Premium Inside Sarissa’s Healthy Returns Why the Tiger Cub and Icahn alum is outperforming other health-care funds. By Stephen Taub July 19, 2021
This content is from: Premium One of the Best-Performing Hedge Funds in Recent Years Just Got Richer Why Avoro Capital Advisors cheered Gilead’s deal to acquire Immunomedics. By Stephen Taub September 16, 2020
This content is from: Premium Have Tesla Shorts Come Back? Not Yet The big short is still in the red for the year — but the stock is still falling. By Michelle Celarier March 09, 2020
This content is from: Corner Office Short Sellers Hurt by Gilead’s Kite Acquisition Kite Pharma has likely been a target for bearish bets because the cancer-fighting technology it uses — CART — is new to the market, says Wedbush biotechnology analyst David Nierengarten. By Alicia McElhaney August 28, 2017
This content is from: Portfolio Gilead Sciences’ Miracle Drug Combination Investors stand to benefit from Gilead’s top-selling hepatitis C and HIV drugs even as the biotech company is trading at a discount. By Vitaliy Katsenelson February 23, 2016
This content is from: Premium Druckenmiller’s Family Office Unloads Two Major Stocks The legendary macro trader established more new positions than it liquidated during the second quarter. By Stephen Taub August 28, 2018
